B-Cell Lymphoma
Symptoms, Doctors, Treatments, Advances & More

B-Cell Lymphoma Overview

Save information for later
Sign Up

Learn About B-Cell Lymphoma

What is the definition of B-Cell Lymphoma?
B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterized by abnormalities of the "B-cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. When present, signs and symptoms may include swollen lymph nodes in the neck, armpit, or groin; abdominal pain; fatigue; fever; night sweats; and/or weight loss. The underlying cause of B-cell lymphoma is poorly understood. However, the condition can be associated with genetic abnormalities, environmental factors, viruses, immunodeficiency states, and connective-tissue disorders.
What are the alternative names for B-Cell Lymphoma?
  • B-cell lymphoma
  • Lymphoma, B-Cell
Who are the top B-Cell Lymphoma Local Doctors?
Stephen J. Schuster
Elite in B-Cell Lymphoma
Dr. Stephen J. Schuster
Hematology
Elite in B-Cell Lymphoma
Dr. Stephen J. Schuster
Hematology

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Schuster is a Hematologist in Philadelphia, Pennsylvania. Dr. Schuster is rated as an Elite provider by MediFind in the treatment of B-Cell Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Paolo Caimi
Elite in B-Cell Lymphoma
Dr. Paolo Caimi
Hematology Oncology | Hematology | Oncology
Elite in B-Cell Lymphoma
Dr. Paolo Caimi
Hematology Oncology | Hematology | Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
866-223-8100
Languages Spoken:
English, Spanish
See accepted insurances

Paolo Caimi is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Caimi is rated as an Elite provider by MediFind in the treatment of B-Cell Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

 
 
 
 
Learn about our expert tiers
Learn More
Daniel J. Landsburg
Elite in B-Cell Lymphoma
Dr. Daniel J. Landsburg
Hematology
Elite in B-Cell Lymphoma
Dr. Daniel J. Landsburg
Hematology

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Landsburg is a Hematologist in Philadelphia, Pennsylvania. Dr. Landsburg is rated as an Elite provider by MediFind in the treatment of B-Cell Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Landsburg is currently accepting new patients.

View All Doctors
What are the latest B-Cell Lymphoma Clinical Trials?
A Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
A Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Biological
Study Phase: Phase 1

Summary: Diffuse large B-cell lymphoma is the most commonly occurring subtype of non-Hodgkin lymphoma, but treatment is often not curative, with as many as 50% of patients with adverse risk factors developing relapsed/refractory disease. CAR T-cell therapy has revolutionized modern cancer therapy, with axicabtagene ciloleucel and lisocabtagene maraleucel (anti-CD19 CAR T-cell therapies) FDA approved for se...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1 Study of Nivolumab in Combination With ASTX727 in B-cell Lymphoma (NHL or HL) With an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)
A Phase 1 Study of Nivolumab in Combination With ASTX727 in B-cell Lymphoma (NHL or HL) With an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)
Who is this study for: Patients with relapsed or refractory diffuse large B-cell lymphoma
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Biological, Drug, Procedure
Study Drugs: Decitabine, Cedazuridine, Nivolumab
Study Phase: Phase 1

Summary: This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ASTX7...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center